Rare and common variants of APOB and PCSK9 in Korean patients with extremely low low-density lipoprotein-cholesterol levels

被引:16
|
作者
Lee, Chan Joo [1 ,2 ]
Lee, Yunbeom [3 ]
Park, Sungha [1 ,2 ]
Kang, Seok-Min [1 ,2 ]
Jang, Yangsoo [1 ,2 ]
Lee, Ji Hyun [4 ]
Lee, Sang-Hak [1 ,2 ]
机构
[1] Yonsei Univ, Coll Med, Severance Hosp, Div Cardiol,Dept Internal Med, Seoul, South Korea
[2] Yonsei Univ, Coll Med, Cardiovasc Res Inst, Seoul, South Korea
[3] Kyung Hee Univ, Grad Sch, Dept Med, Seoul, South Korea
[4] Kyung Hee Univ, Coll Med, Dept Clin Pharmacol & Therapeut, Seoul, South Korea
来源
PLOS ONE | 2017年 / 12卷 / 10期
基金
新加坡国家研究基金会;
关键词
APOLIPOPROTEIN-B; GENETIC-VARIANTS; FAMILIAL HYPOBETALIPOPROTEINEMIA; MOLECULAR DIAGNOSIS; HEART-DISEASE; FATTY LIVER; LOW LDL; MUTATIONS; JAPANESE; DYSLIPIDEMIAS;
D O I
10.1371/journal.pone.0186446
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Background Screening of variants, related to lipid metabolism in patients with extreme cholesterol levels, is a tool used to identify targets affecting cardiovascular outcomes. The aim of this study was to examine the prevalence and characteristics of rare and common variants of APOB and PCSK9 in Korean patients with extremely low low-density lipoprotein-cholesterol (LDLC) levels. Methods Among 13,545 participants enrolled in a cardiovascular genome cohort, 22 subjects, whose LDL-C levels without lipid-lowering agents were <= 1 percentile (48 mg/dL) of Korean population, were analyzed. Two target genes, APOB and PCSK9, were sequenced by targeted next-generation sequencing. Prediction of functional effects was conducted using SIFT, PolyPhen-2, and Mutation Taster, and matched against a public database of variants. Results Eight rare variants of the two candidate genes (five in APOB and three in PCSK9) were found in nine subjects. Two subjects had more than two different rare variants of either gene (one subject in APOB and another subject in APOB/PCSK9). Conversely, 12 common variants (nine in APOB and three in PCSK9) were discovered in 21 subjects. Among all variants, six in APOB and three in PCSK9 were novel. Several variants previously reported functional, including c. C277T (p. R93C) and c. G2009A (p. G670E) of PCSK9, were found in our population. Conclusions Rare variants of APOB or PCSK9 were identified in nine of the 22 study patients with extremely low LDL-C levels, whereas most of them had common variants of the two genes.The common novelty of variants suggested polymorphism of the two genes among them. Our results provide rare genetic information associated with this lipid phenotype in East Asian people.
引用
收藏
页数:13
相关论文
共 50 条
  • [1] Insights Into PCSK9, Low-Density Lipoprotein Receptor, and Low-Density Lipoprotein Cholesterol Metabolism: Of Mice and Man
    Stein, Evan A.
    Raal, Frederick J.
    CIRCULATION, 2013, 127 (24) : 2372 - 2374
  • [2] The Influence of PCSK9 Polymorphisms on Serum Low-Density Lipoprotein Cholesterol and Risk of Atherosclerosis
    Davignon, Jean
    Dubuc, Genevieve
    Seidah, Nabil G.
    CURRENT ATHEROSCLEROSIS REPORTS, 2010, 12 (05) : 308 - 315
  • [3] The Influence of PCSK9 Polymorphisms on Serum Low-Density Lipoprotein Cholesterol and Risk of Atherosclerosis
    Jean Davignon
    Geneviève Dubuc
    Nabil G. Seidah
    Current Atherosclerosis Reports, 2010, 12 : 308 - 315
  • [4] Reduction of Low-Density Lipoprotein Cholesterol by Monoclonal Antibody Inhibition of PCSK9
    Stein, Evan A.
    Raal, Frederick
    ANNUAL REVIEW OF MEDICINE, VOL 65, 2014, 65 : 417 - 431
  • [5] Relationship Between Low-Density Lipoprotein Cholesterol and Lipoprotein(a) Lowering in Response to PCSK9 Inhibition With Evolocumab
    Shapiro, Michael D.
    Minnier, Jessica
    Tavori, Hagai
    Kassahun, Helina
    Flower, Andrea
    Somaratne, Ransi
    Fazio, Sergio
    JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2019, 8 (04):
  • [6] Multiple rare and common variants in APOB gene locus associated with oxidatively modified low-density lipoprotein levels
    Khlebus, Eleonora
    Kutsenko, Vladimir
    Meshkov, Alexey
    Ershova, Alexandra
    Kiseleva, Anna
    Shevtsov, Anton
    Shcherbakova, Natalia
    Zharikova, Anastasiia
    Lankin, Vadim
    Tikhaze, Alla
    Chazova, Irina
    Yarovaya, Elena
    Drapkina, Oksana
    Boytsov, Sergey
    PLOS ONE, 2019, 14 (05):
  • [7] Common and Low-Frequency Genetic Variants in the PCSK9 Locus Influence Circulating PCSK9 Levels
    Chernogubova, Ekaterina
    Strawbridge, Rona
    Mahdessian, Hovsep
    Malarstig, Anders
    Krapivner, Sergey
    Gigante, Bruna
    Hellenius, Mai-Lis
    de Faire, Ulf
    Franco-Cereceda, Anders
    Syvaenen, Ann-Christine
    Troutt, Jason S.
    Konrad, Robert J.
    Eriksson, Per
    Hamsten, Anders
    van 't Hooft, Ferdinand M.
    ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2012, 32 (06) : 1526 - +
  • [8] Longitudinal Association of PCSK9 Sequence Variations With Low-Density Lipoprotein Cholesterol Levels The Coronary Artery Risk Development in Young Adults Study
    Huang, Chiang-Ching
    Fornage, Myriam
    Lloyd-Jones, Donald M.
    Wei, Gina S.
    Boerwinkle, Eric
    Liu, Kiang
    CIRCULATION-CARDIOVASCULAR GENETICS, 2009, 2 (04) : 354 - U112
  • [9] Low-density Lipoprotein-Cholesterol Lowering Strategies for Prevention of Atherosclerotic Cardiovascular Disease: Focus on siRNA Treatment Targeting PCSK9 (Inclisiran)
    Sinning, David
    Landmesser, Ulf
    CURRENT CARDIOLOGY REPORTS, 2020, 22 (12)
  • [10] Lowering low-density lipoprotein cholesterol by PCSK9 inhibition in patients with diabetes on insulin therapy: is it efficacious and safe?
    Farnier, Michel
    ANNALS OF TRANSLATIONAL MEDICINE, 2018, 6 (03)